Sonnet BioTherapeutics Enters Into Clinical Collaboration Agreement With The Sarcoma Oncology Center, To Commence Phase 1/2a Study Of SON-1210 in Combination With Chemotherapy For The Treatment Of Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics has entered a clinical collaboration with the Sarcoma Oncology Center to conduct a Phase 1/2a study of SON-1210, a bifunctional IL-12/IL-15 fusion protein, in combination with chemotherapy for pancreatic cancer treatment.
August 19, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics has announced a collaboration with the Sarcoma Oncology Center to initiate a Phase 1/2a study of SON-1210 for pancreatic cancer treatment. This development could enhance Sonnet's pipeline and market position in oncology.
The collaboration to study SON-1210 in pancreatic cancer is a significant step for Sonnet BioTherapeutics, as it addresses a critical unmet medical need. The positive preclinical data and the involvement of renowned oncology experts could lead to successful clinical outcomes, potentially boosting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100